Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Inclusion Criteria: * Patients with ADPKD with polycystic liver (\> 20 liver cysts) * Renal function MDRD \>40 ml/hr * Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements Exclusion Criteria: * Kidney transplantation * Renal failure requiring hemodialysis * Use of oral contraceptives or estrogen suppletion * Women who are pregnant or breastfeeding * History of cardiac/pulmonary disease; symptomatic gallstones, pancreatitis, etc * Intervention (aspiration or surgical intervention) within three months from baseline * Treatment with somatostatin analogues within three months from baseline * Mental illness that interferes with the patient ability to comply with the protocol * Drug or alcohol abuse within one year from baseline * Abnormal liver function tests, as determined by blood test (except isolated elevated GGT and AP, which occurs frequently in PLD) * Clinical diagnosis of pancreatitis * Diagnosis of diabetes mellitus, as determined by blood test and medical history * Use of drugs that can interact with lanreotide, such as cyclosporin